MHRA expands work-sharing pathway for faster medicine reviews
The MHRA has updated its guidance on the New Active Substance Work Sharing Initiative and the Biosimilar Work Sharing Initiative, two Access Consortium pathways designed to coordinate regulatory assessment across multiple jurisdictions. The framework is built to reduce duplicated review work, increase regulatory capacity, and keep high-quality medicines moving through the approval process without sacrificing national decision-making. In practice, it offers companies a structured route for simultaneous submissions and coordinated scientific review across participating regulators in the United Kingdom, Australia, Canada, Singapore, and Switzerland.
The page now carries a long list of successful NASWSI approvals, ranging from oncology and immunology to ophthalmology, kidney disease, cystic fibrosis, and neurology. The breadth matters. It shows that the initiative is no longer a narrow administrative experiment; it has become a functioning international review channel for both complex biologics and small molecules, including products for relapsing multiple sclerosis, pulmonary arterial hypertension, hereditary angioedema, and metastatic colorectal cancer.
Coordinated review, but national decisions remain separate
The core mechanics are straightforward. An applicant first signals interest 3 to 6 months before submission using the appropriate expression of interest form. After that, identical dossiers are sent to the participating authorities, ideally within a two-week window. The UK submission must arrive in eCTD format and align with domestic regulatory requirements, while country-specific differences are documented in the summary of differences between dossiers. Once the main review is completed, evaluation reports are shared through a secure platform, peer review follows, and the regulators discuss the findings in teleconference before issuing a consolidated response to the applicant.
Product labelling is handled differently. It is not part of the joint scientific review, and each agency retains authority to determine label language on a national basis because legal and regulatory requirements differ across countries. Clarification questions are handled in parallel when the standard review pathway is used, while the priority review pathway for NAS submissions directs questions back to the respective local affiliate and shares them with the partner regulator so the dossier can remain complete for all parties.
A joint scientific process does not erase regulatory sovereignty.
That structure is clinically relevant because it allows shared scrutiny of quality, safety, and efficacy while preserving the local checks that govern how a product is ultimately licensed and described for prescribers and patients. It also explains why approval in one Access Consortium jurisdiction does not automatically determine the outcome, or the timing, in another. Each regulator makes an independent final decision, and national procedures still apply to public summaries such as the UK Public Assessment Report, AusPAR, Canadian Summary Basis of Decision, and SwissPAR.
The approvals list spans major therapeutic areas
The updated approvals table offers a snapshot of what this pathway has already delivered. Vabysmo appears twice, first for neovascular age-related macular degeneration and diabetic macular oedema, then later for visual impairment due to macular oedema secondary to retinal vein occlusion. Scemblix gained initial approval for adults with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after at least two prior tyrosine kinase inhibitors, excluding known T315I mutation. Orkambi granules were extended to younger children with cystic fibrosis who are homozygous for F508del in the CFTR gene.
The oncology portfolio is especially visible. Brukinsa carries indications across Waldenström’s macroglobulinaemia, marginal zone lymphoma, chronic lymphocytic leukaemia, and relapsed or refractory follicular lymphoma when combined with obinutuzumab. Fruzaqla is listed for previously treated metastatic colorectal cancer, including patients who have already received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. These are not incremental administrative edits; they represent treatment access in diseases where sequencing matters and where the line between exhausted options and active therapy can be clinically decisive.
Other additions widen access into chronic inflammatory and immune-mediated disease. Dupixent now carries a chronic spontaneous urticaria indication in patients 12 years and older whose disease is not adequately controlled with H1 antihistamines. Nemluvio covers moderate-to-severe atopic dermatitis alongside topical therapy in eligible patients and also adult prurigo nodularis. Lynkuet has been expanded twice, first for moderate to severe menopausal vasomotor symptoms and later for vasomotor symptoms caused by adjuvant endocrine therapy related to breast cancer. The endocrine-treatment-related indication is particularly practical because hot flushes and night sweats can drive discontinuation, threaten adherence, and erode quality of life during cancer treatment.
The recent additions point to deeper specialty demand
The newest entries extend the initiative into additional specialty areas. Ocrevus now includes paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis, while Onswik has been added for adults with type 2 diabetes mellitus. The appearance of a paediatric multiple sclerosis indication is notable because it signals a growing recognition that coordinated international review can support therapies for rarer age-specific populations as well as large adult markets.
The list also includes Andembry for routine prevention of recurrent hereditary angioedema attacks in adults and adolescents 12 years and older, Ekterly for hereditary angioedema attacks in adults and adolescents 12 years and older, and Opusmit for long-term treatment of paediatric pulmonary arterial hypertension in children aged 2 years to less than 18 years with WHO functional class II to III. Each of these conditions sits in a niche where treatment access can be time-sensitive and where an efficient review pathway may matter as much as the science behind the molecule.
Regulatory work-sharing does not change the biology of the disease, but it can change how quickly a proven therapy reaches the bedside. For chronic illnesses with narrow windows for intervention, fewer delays in assessment can translate into earlier initiation, fewer untreated months, and a smoother path from clinical development to routine care.
Practical instructions still govern how sponsors enter the pathway
The guidance remains operational as much as scientific. Sponsors are instructed to contact the relevant regional authority with the appropriate expression of interest form 3 to 6 months before submission. For NASWSI, communications must carry the subject line “Access Consortium – NASWSI”; for BSWSI, the subject line must read “Access Consortium – BSWSI”. National fees apply, and the MHRA points applicants back to the relevant UK requirements for medicine licensing and submission formatting.
The arrangement depends on discipline from both regulators and applicants. The dossier must be coordinated, the country-specific elements must be transparent, and the timeline must be respected. Where those conditions are met, the Access Consortium model creates a review environment that can pool expertise without flattening jurisdictional differences.
What the page does not do is promise speed at the expense of scrutiny. The model is deliberately built around shared work, separate labels, separate legal obligations, and independent final decisions. That is the constraint, and it is also the safeguard.